Long-term safety of adalimumab for patients with moderate-to-severe hidradenitis suppurativa

References

• Saunte DML. Jemec GBE hidradenitis suppurativa: advances in diagnosis and treatment. JAMA. 2017;318:2019–2032.
   PubMed Web of Science ®Google Scholar
• Kurzen H, Kurokawa I, Jemec GB, et al. What causes hidradenitis suppurativa? Exp Dermatol. 2008;17:455–472.
   PubMed Web of Science ®Google Scholar
• Garg A, Kirby JS, Lavian J, et al. Sex- and age-adjusted population analysis of 386 prevalence estimates for hidradenitis suppurativa in the United States. JAMA Dermatol. 2017;153:760–764.
   PubMed Web of Science ®Google Scholar
• Garg A, Lavian J, Lin G, et al. Incidence of hidradenitis suppurativa in the United States: a sex- and age-adjusted population analysis. J Am Acad Dermatol. 2017;77:118–122.
   PubMed Web of Science ®Google Scholar
• Kirsten N, Petersen J, Hagenström K, et al. Epidemiology of hidradenitis suppurativa in Germany - an observational cohort study based on a multisource approach. J Eur Acad Dermatol Venereol. 2019. DOI:10.1111/jdv.1594
   Google Scholar
• Calao M, Wilson JL, Spelman L, et al. Hidradenitis Suppurativa (HS) prevalence, demographics and management pathways in Australia: a population-based cross-sectional study. PLoS One. 2018;1:e0200683.
   Google Scholar
• Vinding GR, Miller IM, Zarchi K, et al. The prevalence of inverse recurrent suppuration: a population-based study of possible hidradenitis suppurativa. Br J Dermatol. 2014;170:884–889.
   PubMed Web of Science ®Google Scholar
• Revuz JE, Canoui-Poitrine F, Wolkenstein P, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol. 2008;59:596–601.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375:422–434.
   PubMed Web of Science ®Google Scholar
• Guet-Revillet H, Coignard-Biehler H, Jais JP, et al. Bacterial pathogens associated with hidradenitis suppurativa, France. Emerg Infect Dis. 2014;20:1990–1998.
   PubMed Web of Science ®Google Scholar
• Garg A, Birabaharan M, Strunk A. Prevalence of type 2 diabetes mellitus among patients with hidradenitis suppurativa in the United States. J Am Acad Dermatol. 2018;79:71–76.
   PubMed Web of Science ®Google Scholar
• Deckers IE, Benhadou F, Koldijk MJ, et al. Inflammatory bowel disease is associated with hidradenitis suppurativa: results from a multicenter cross-sectional study. J Am Acad Dermatol. 2017;76:49–53.
   PubMed Web of Science ®Google Scholar
• Miller IM, Ellervik C, Vinding GR, et al. Association of metabolic syndrome and hidradenitis suppurativa. JAMA Dermatol. 2014;150:1273–1280.
   PubMed Web of Science ®Google Scholar
• Matusiak L, Bieniek A, Szepietowski JC. Increased serum tumour necrosis factor-alpha in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-alpha agents? Acta Derm Venereol. 2009;89:601–603.
   PubMed Web of Science ®Google Scholar
• van der Zee HH, de Ruiter L, van den Broecke DG, et al. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. Br J Dermatol. 2011;164:1292–1298.
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis EJ, Antonopoulou A, Petropoulou C, et al. Altered innate and adaptive immune responses in patients with hidradenitis suppurativa. Br J Dermatol. 2007;156(1):51–56.
   PubMed Web of Science ®Google Scholar
• Kanni T, Tzanetakou V, Savva A, et al. Compartmentalized cytokine responses in hidradenitis suppurativa. PLoS One. 2015;10:e0130522.
   PubMed Web of Science ®Google Scholar
• Kanni T, Zenker O, Habel M, et al. Complement activation in hidradenitis suppurativa: a new pathway of pathogenesis? Br J Dermatol. 2018;179:413–419.
   PubMed Web of Science ®Google Scholar
• HUMIRA® (adalimumab) ǀ A biologic treatment option: Full prescribing information. 2019 [cited 2019 Dec 9]. Available from: https://www.rxabbvie.com/pdf/humira.pdf
   Google Scholar
• van der Zee HH, Laman JD, de Ruiter L, et al. Adalimumab (antitumour necrosis factor alpha) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study. Br J Dermatol. 2012;166:298–305.
   PubMed Web of Science ®Google Scholar
• Miller I, Lynggaard CD, Lophaven S, et al. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. Br J Dermatol. 2011;165(2):391–398.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Kerdel F, Adams D, et al. Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med. 2012;157:846–855.
   PubMed Web of Science ®Google Scholar
• Nader A, Beck D, Noertersheuser P, et al. Population pharmacokinetics and immunogenicity of adalimumab in adult patients with moderate-to-severe hidradenitis suppurativa. Clin Pharmacokinet. 2017;56:1091–1102.
   PubMed Web of Science ®Google Scholar
• Amano M, Grant A, Kerdel FA. A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa. Int J Dermatol. 2010;49(8):950–955.
   PubMed Web of Science ®Google Scholar
• Sotiriou E, Goussi C, Lallas A, et al. A prospective open-label clinical trial of efficacy of the every week administration of adalimumab in the treatment of hidradenitis suppurativa. J Drugs Dermatol. 2012;11(5 Suppl):s15–20.
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Okun MM, Prens EP, et al. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study. J Am Acad Dermatol. 2019;80:60–69.
   PubMed Web of Science ®Google Scholar
• Morita A, Takahashi H, Ozawa K, et al. Twenty-four-week interim analysis from a phase 3 open-label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa. J Dermatol. 2019;46:745–751.
   PubMed Web of Science ®Google Scholar
• Blanco R, Martinez-Taboada VM, Villa I, et al. Long-term successful adalimumab therapy in severe hidradenitis suppurativa. Arch Dermatol. 2009;145:580–584.
   PubMed Web of Science ®Google Scholar
• Kyriakou A, Trigoni A, Galanis N, et al. Efficacy of adalimumab in moderate to severe hidradenitis suppurativa: real life data. Dermatol Rep. 2018;10:7859.
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis EJ, Pelekanou E, Antonopoulou A, et al. An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa. Br J Dermatol. 2008;158:567–572.
   PubMed Web of Science ®Google Scholar
• Grant A, Gonzalez T, Montgomery MO, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol. 2010;62:205–217.
   PubMed Web of Science ®Google Scholar
• Arenbergerova M, Gkalpakiotis S, Arenberger P. Effective long-term control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapy. Int J Dermatol. 2010;49:1445–1449.
   PubMed Web of Science ®Google Scholar
• Jiménez-Gallo D, de la Varga-martínez R, Ossorio-García L, et al. Effects of adalimumab on T-helper-17 lymphocyte- and neutrophil-related inflammatory serum markers in patients with moderate-to-severe hidradenitis suppurativa. Cytokine. 2018;103:20–24.
   PubMed Web of Science ®Google Scholar
• Ryan C, Sobell JM, Leonardi CL, et al. Safety of Adalimumab dosed every week and every other week: focus on patients with hidradenitis suppurativa or psoriasis. Am J Clin Dermatol. 2018;19:437–447.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Gordon KB, Rosenbaum JT, et al. Long-term safety of adalimumab in 29,967 adult patients from global clinical trials across multiple indications: an updated analysis. Adv Ther. 2019. DOI: 10.1007/s12325-019-01145-8
   PubMed Web of Science ®Google Scholar
• Jemec GBE, Okun MM, Forman SB, et al. Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials. Br J Dermatol. 2019;181:967–975.
   PubMed Web of Science ®Google Scholar
• Rahman MM, McFadden G. Modulation of tumor necrosis factor by microbial pathogens. PLoS Pathog. 2006;2:e4.
   PubMed Web of Science ®Google Scholar
• Giamarellos-Bourboulis EJ, Sobell J, Ryan C, et al. Infection-free clinical response among patients with hidradenitis suppurativa who were treated with adalimumab: results from two phase 3 studies. Wounds. 2017;29:E98–102.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Fan W, Yang G, et al. Risk of tuberculosis in patients treated with TNF-α antagonists: a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2017;7:e012567.
   PubMed Web of Science ®Google Scholar
• Cortez de Almeida RF, Cortez Cardoso Penha R, do Nascimento Barbosa L. Two cases of disseminated tuberculosis after negative screening before adalimumab treatment for immune-mediated inflammatory diseases. JAAD Case Rep. 2019;5:1002–1005.
   PubMedGoogle Scholar
• Lee HH, Patel KR, Singam V, et al. Associations of cutaneous and extracutaneous infections with hidradenitis suppurativa in U.S. children and adults. Br J Dermatol. 2019. DOI:10.1111/bjd.18093.
   Google Scholar
• Piaserico S, Dapavo P, Conti A, et al. Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature. J Eur Acad Dermatol Venereol. 2017;31:1853–1859.
   PubMed Web of Science ®Google Scholar
• Tumor necrosis factor antagonists. LiverTox: clinical and research information on drug-induced liver injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–2017.
   Google Scholar
• Molina-Leyva A, Badiola J. Severe refractory hidradenitis suppurativa successfully treated with adalimumab in an HIV-positive/hepatitis C virus-positive patient. AIDS. 2018;32:2436–2438.
   PubMed Web of Science ®Google Scholar
• Pena ZG, Sivamani RK, Konia TH, et al. Squamous cell carcinoma in the setting of chronic hidradenitis suppurativa; report of a patient and update of the literature. Dermatol Online J. 2015;21:pii: 13030/qt9q9707dp.
   PubMedGoogle Scholar
• Lavogiez C, Delaporte E, Darras-Vercambre S, et al. Clinicopathological study of 13 cases of squamous cell carcinoma complicating hidradenitis suppurativa. Dermatology. 2010;220:147–153.
   PubMed Web of Science ®Google Scholar
• Lapins J, Ye W, Nyren O, et al. Incidence of cancer among patients with hidradenitis suppurativa. Arch Dermatol. 2001;137(6):730–734.
   PubMedGoogle Scholar
• Giesey R, Delost GR, Honaker J, et al. Metastatic squamous cell carcinoma in a patient treated with adalimumab for hidradenitis suppurativa. JAAD Case Rep. 2017;3:489–491.
   PubMedGoogle Scholar
• Bessaleli E, Scheinfeld N, Kroumpouzos G. Squamous cell carcinoma of the cervix arising in a patient on adalimumab - a need for cervical screenings in patients on tumor necrosis factor inhibitors. Dermatol Online J. 2018;24:pii: 13030/qt3fs049h2.
   Google Scholar
• Zhao CY, Fernández-Peñas P. Is it worthy to treat hidradenitis suppurativa with adalimumab in patients with melanoma and other debilitating systemic diseases? A series of clinical dilemmas. Australas J Dermatol. 2018;59:e297–98.
   PubMed Web of Science ®Google Scholar
• Puxeddu I, Giori L, Rocchi V, et al. Hypersensitivity reactions during treatment with infliximab, etanercept, and adalimumab. Ann Allergy Asthma Immunol. 2012;108:123–124.
   PubMed Web of Science ®Google Scholar
• Pérez-De-Lis M, Retamozo S, Flores-Chávez A, et al. Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS registry). Expert Opin Drug Saf. 2017;16:1255–1271.
   PubMed Web of Science ®Google Scholar
• Brown G, Wang E, Leon A, et al. Tumor necrosis factor-α inhibitor-induced psoriasis: systematic review of clinical features, histopathological findings, and management experience. J Am Acad Dermatol. 2017;76:334–341.
   PubMed Web of Science ®Google Scholar
• Patel M, Cohen JM, Wright NA, et al. Epidemiology of concomitant psoriasis and hidradenitis suppurativa (HS): experience of a tertiary medical center. J Am Acad Dermatol. 2015;73:701–702.
   PubMed Web of Science ®Google Scholar
• Dequidt L, Cogrel O, Guillet S, et al. Paradoxical psoriasiform reactions to antitumour necrosis factor-α drugs in hidradenitis suppurativa. Br J Dermatol. 2018;178:281–283.
   PubMed Web of Science ®Google Scholar
• Company-Quiroga J, Alique-García S, Martínez-Morán C, et al. Adalimumab-induced pyoderma gangrenosum in a patient with hidradenitis suppurativa: a paradoxical reaction. Indian J Dermatol Venereol Leprol. 2019;85:422–425.
   PubMed Web of Science ®Google Scholar
• Benhadou F, Hellgren G, Willaert F, et al. Acute erythroderma in a patient receiving TNF-α-blocking therapy for hidradenitis suppurativa. Case Rep Dermatol. 2018;31(10):7–12.
   Google Scholar
• van der Zee HH, Longcore M, Geng Z, et al. Weekly adalimumab treatment decreased disease flare in hidradenitis suppurativa over 36 weeks: integrated results from the phase 3 PIONEER trials. J Eur Acad Dermatol Venereol. 2019. DOI:10.1111/jdv.16023
   Google Scholar
• Caposiena Caro RD, Cannizzaro MV, Tartaglia C, et al. Clinical response rate and flares of hidradenitis suppurativa in the treatment with adalimumab. Clin Exp Dermatol. 2019. DOI:10.1111/ced.14127
   Web of Science ®Google Scholar
• Segura Palacios JM, García Montero P, Fúnez Liébana R, et al. Human papilloma virus and the risk of squamous cell carcinoma arising in hidradenitis suppurativa. Actas Dermosifiliogr. 2018;109:457–459.
   PubMed Web of Science ®Google Scholar
• Nikkels A, Lebas E. Should we provide anti-human papillomavirus vaccination for patients with genital hidradenitis suppurativa? Br J Dermatol. 2019;180:233.
   PubMed Web of Science ®Google Scholar
• Mikkelsen PR, Jemec GB. Hidradenitis suppurativa in children and adolescents: a review of treatment options. Paediatr Drugs. 2014;1:483–489.
   Google Scholar
• Sahu P, Aggarwal P, Dayal S, et al. Biologic therapy: a boon for hidradenitis suppurativa-like lesions complicating naevus comedonicus in a prepubertal child. Clin Exp Dermatol. 2019;44:322–324.
   PubMed Web of Science ®Google Scholar
• Bi Y, Liu J, Wang J, et al. Model-informed drug development approach supporting approval of adalimumab (HUMIRA) in adolescent patients with hidradenitis suppurativa: a regulatory perspective. AAPS J. 2019;21:91.
   PubMed Web of Science ®Google Scholar
• Oranges T, Chiricozzi A, Iannone M, et al. Long-term outcome of adalimumab in a young girl with hidradenitis suppurativa. Skin Appendage Disord. 2018;5:538–541.
   Web of Science ®Google Scholar
• Seow CH, Leung Y, Vande Casteele N, et al. The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45:1329–1338.
   PubMed Web of Science ®Google Scholar
• Esteve-Solé A, Deyà-Martínez À, Teixidó I, et al. Immunological changes in blood of newborns exposed to anti-TNF-α during pregnancy. Front Immunol. 2017;8:1123.
   PubMed Web of Science ®Google Scholar
• Weber-Schoendorfer C, Oppermann M, Wacker E, et al. Pregnancy outcome after TNF-α inhibitor therapy during the first trimester: a prospective multicentre cohort study. Br J Clin Pharmacol. 2015;80:727–739.
   PubMed Web of Science ®Google Scholar
• Hoxha A, Calligaro A, Di Poi E, et al. Pregnancy and foetal outcomes following anti-tumor necrosis factor alpha therapy: a prospective multicentre study. Joint Bone Spine. 2017;84:169–173.
   PubMed Web of Science ®Google Scholar
• Horst S, Kane S. The use of biologic agents in pregnancy and breastfeeding. Gastroenterol Clin North Am. 2014;43:495–508.
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Yavzori M, Katz L, et al. Adalimumab level in breast milk of a nursing mother. Clin Gastroenterol Hepatol. 2010;8:475–476.
   PubMed Web of Science ®Google Scholar
• Esposito M, Giunta A, Mazzotta A, et al. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study. Dermatology. 2012;225(4):312–319.
   PubMed Web of Science ®Google Scholar
• Matsui T, Umetsu R, Kato Y, et al. Age-related trends in injection site reaction incidence induced by the tumor necrosis factor-α (TNF-α) inhibitors etanercept and adalimumab: the Food and Drug Administration adverse event reporting system, 2004–2015. Int J Med Sci. 2017;14:102–109.
   PubMed Web of Science ®Google Scholar
• Lobatón T, Ferrante M, Rutgeerts P, et al. Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2015;42:441–451.
   PubMed Web of Science ®Google Scholar
• Husein-ElAhmed H, Fernandez-Pugnaire MA, Ruiz-Carrascosa JC. Severe hidradenitis suppurativa in an HIV-positive male: use of multiple treatment modalities, including tumor necrosis factor blockade. AIDS Patient Care STDS. 2011;25:507–508.
   PubMed Web of Science ®Google Scholar
• Alecsandru D, Padilla B, Izquierdo JA, et al. Severe refractory hidradenitis suppurativa in an HIV-positive patient successfully treated with infliximab. Arch Dermatol. 2010;146:1343–1345.
   PubMed Web of Science ®Google Scholar
• Gallitano SM, McDermott L, Brar K, et al. Use of tumor necrosis factor (TNF) inhibitors in patients with HIV/AIDS. J Am Acad Dermatol. 2016;74:974–980.
   PubMed Web of Science ®Google Scholar
• Sumida K, Ubara Y, Suwabe T, et al. Adalimumab treatment in patients with rheumatoid arthritis with renal insufficiency. Arthritis Care Res (Hoboken). 2013;65:4715.
   Web of Science ®Google Scholar
• De Wet J, Jordan HF, Kannenberg SM, et al. Pyoderma gangrenosum, acne, and suppurative hidradenitis syndrome in end-stage renal disease successfully treated with adalimumab. Dermatol Online J. 2017;23:pii: 13030/qt82d4m2zw.
   PubMedGoogle Scholar
• Sbidian E, Hotz C, Seneschal J, et al. Antitumour necrosis factor-α therapy for hidradenitis suppurativa: results from a national cohort study between 2000 and 2013. Br J Dermatol. 2016;174:667–670.
   PubMed Web of Science ®Google Scholar
• Martin-Ezquerra G, Masferrer E, Masferrer-Niubò M, et al. Use of biological treatments in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2015;29:56–60.
   PubMed Web of Science ®Google Scholar
• van Rappard DC, Leenarts MF, Meijerink-van ‘t Oost L, et al. Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa. J Dermatolog Treat. 2012;23:284–289.
   PubMed Web of Science ®Google Scholar
• Marasca C, Annunziata MC, Villani A, et al. Adalimumab versus rifampicin plus clindamycin for the treatment of moderate to severe hidradenitis suppurativa: a retrospective study. J Drugs Dermatol. 2019;18:437–438.
   PubMed Web of Science ®Google Scholar